Old Web
English
Sign In
Acemap
>
authorDetail
>
L Y Hao
L Y Hao
Janssen Pharmaceutica
Physical therapy
Medicine
Diabetes mellitus
Immunology
Ulcerative colitis
3
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
AB0037 EXPRESSION OF NEGATIVE CHECKPOINT MOLECULES BTLA AND HVEM IS DYSREGULATED IN AUTOIMMUNE DISEASES
2020
Annals of the Rheumatic Diseases
Sunil Nagpal
Suzanne Cole
Achilleas Floudas
Mihir D. Wechalekar
Qingxuan Song
Tom P. Gordon
Roberto Caricchio
Douglas J. Veale
Ursula Fearon
Navin Rao
L Y Hao
Show All
Source
Cite
Save
Citations (0)
DOP53 Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
2019
Journal of Crohns & Colitis
William J. Sandborn
Deanna Nguyen
Brian Ferslew
L Y Hao
T Kanno
L Tomsho
D Boyle
Richard Graham
B. Abhyankar
Julián Panés
Show All
Source
Cite
Save
Citations (5)
P849 Genetic variation within the NKG2D pathway may influence the response to anti-NKG2D therapy in Crohn’s disease
2018
Journal of Crohns & Colitis
A Hart
Eric M. Neiman
Jacqueline Perrigoue
L Y Hao
L Tomsho
W Schultz
A Di Narzo
Ke Hao
B Skolnick
T Ort
Mark Curran
Scott E. Plevy
Matthieu Allez
Show All
Source
Cite
Save
Citations (0)
1